Capital Fund Management (CFM)
MLYS icon

Capital Fund Management (CFM)’s Mineralys Therapeutics MLYS Stock Holding History

Capital Fund Management (CFM)’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$428K Sell
15,848
-86,354
-84% -$2.37M ﹤0.01% 1928
2026
Q1 		$2.77M Buy
+102,202
New +$3M 0.01% 1198

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Capital Fund Management (CFM)'s MLYS Position: Q2 2026 in Review

Capital Fund Management (CFM) reduced its Mineralys Therapeutics (MLYS) stake by 84% in Q2 2026, selling an estimated $2.37M and leaving 15,848 shares worth $428K. The position accounts for ﹤0.01% of the portfolio, ranked #1928.

Capital Fund Management (CFM) first reported a position in MLYS in Q1 2026 and has held it in 2 quarters since. The position peaked at $2.77M in Q1 2026. 226 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • Capital Fund Management (CFM) held 15,848 shares of Mineralys Therapeutics worth $428K as of Q2 2026.
  • Capital Fund Management (CFM) sold 86,354 Mineralys Therapeutics shares in Q2 2026, an estimated $2.37M.
  • Mineralys Therapeutics made up ﹤0.01% of Capital Fund Management (CFM)'s portfolio in Q2 2026, its #1928 holding.
  • Capital Fund Management (CFM) first reported a position in Mineralys Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Capital Fund Management (CFM)'s Mineralys Therapeutics position peaked at $2.77M in Q1 2026.
  • 226 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on Capital Fund Management (CFM)'s 13F filing for Q2 2026, filed 13 Aug 2026.